⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19608817 | 0.92 | — | — | |
| SCHEMBL10005842 | 0.92 | — | — | |
| SCHEMBL1644129 | 0.92 | — | — | |
| SCHEMBL10005840 | 0.92 | — | — | |
| SCHEMBL12674234 | 0.92 | — | — | |
| SCHEMBL1642430 | 0.92 | — | — | |
| SCHEMBL19768566 | 0.88 | IGF2R (0.35) | — | |
| SCHEMBL12243052 | 0.87 | — | — | |
| SCHEMBL13998597 | 0.87 | — | — | |
| SCHEMBL1642428 | 0.86 | ITPR3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040493-B2 | RNA antagonists targeting GLI2 for the treatment of leukemia | SANTARIS PHARMA A/S (DK) | 2015-05-26 | — | — | US | disclosed |
| US-20120295955-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | SANTARIS PHARMA A/S (DK) | 2012-11-22 | — | — | US | disclosed |
| US-20120232132-A1 | RNA ANTAGONISTS TARGETING GLI2 FOR THE TREATMENT OF LEUKEMIA | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2012-09-13 | — | — | US | disclosed |